Implications of MDSCs-targeting in lung cancer chemo-immunotherapeutics.
作者： Dickson Adah , Muzammal Hussain , Limei Qin , Li Qin , Jiancun Zhang
DOI: 10.1016/J.PHRS.2016.05.007
关键词:
摘要: Despite advances in chemotherapy and immunotherapy, advanced lung cancer remains an incurable disease. Novel trends anticancer therapeutics focus on harnessing the therapeutically-targeted tumor-related immune suppression. In this respect, myeloid-derived suppressor cells (MDSCs) have captured considerable attention last few years, as they are vividly implicated tumor escape mechanisms. review, we specifically discuss multifaceted roles of MDSCs microenvironment, encompassing growth progression via suppression anti-tumor immunity, association with worse prognosis, hampering efficacy immunotherapy. addition, also that therapeutic manipulation MDSCs-targeting, either alone or combination chemo- and/or immune-therapeutic regimens, may not only inhibition, anti-angiogenesis anti-metastasis effects, but potential to enhance
sci-hub.se 参考文章(143)
Y Yörük, E Cakir, F Yorulmaz, S Gülen, None, Arginase and ornithine, as markers in human non-small cell lung carcinoma. Cancer biochemistry biophysics. ,vol. 17, pp. 125- 131 ,(1999)
Sergei A. Kusmartsev, I. N. Kusmartseva, S. G. Afanasyev, N. V. Cherdyntseva, Immunosuppressive cells in bone marrow of patients with stomach cancer. Advances in Experimental Medicine and Biology. ,vol. 451, pp. 189- 194 ,(1998) , 10.1007/978-1-4615-5357-1_30
Sergio Scrimini, Jaume Pons, Alvar Agustí, Antonio Clemente, Marta Crespí Sallán, Josep Miquel Bauçà, Joan B. Soriano, Borja G. Cosio, Meritxel Lopez, Catalina Crespi, Jaume Sauleda, Expansion of myeloid-derived suppressor cells in chronic obstructive pulmonary disease and lung cancer: potential link between inflammation and cancer. Cancer Immunology, Immunotherapy. ,vol. 64, pp. 1261- 1270 ,(2015) , 10.1007/S00262-015-1737-X
Lihua Huang, Liwu Fu, Mechanisms of resistance to EGFR tyrosine kinase inhibitors Acta Pharmaceutica Sinica B. ,vol. 5, pp. 390- 401 ,(2015) , 10.1016/J.APSB.2015.07.001
P.M. Ellis, N. Coakley, R. Feld, S. Kuruvilla, Y.C. Ung, Use of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the treatment of non-small-cell lung cancer: a systematic review. Current Oncology. ,vol. 22, pp. 183- 215 ,(2015) , 10.3747/CO.22.2566
Ada G. Blidner, Mariana Salatino, Ivan D. Mascanfroni, Miriam J. Diament, Elisa Bal de Kier Joffé, Maria A. Jasnis, Slobodanka M. Klein, Gabriel A. Rabinovich, Differential Response of Myeloid-Derived Suppressor Cells to the Nonsteroidal Anti-Inflammatory Agent Indomethacin in Tumor-Associated and Tumor-Free Microenvironments Journal of Immunology. ,vol. 194, pp. 3452- 3462 ,(2015) , 10.4049/JIMMUNOL.1401144
Pauline L de Goeje, Koen Bezemer, Marlies E Heuvers, Anne-Marie C Dingemans, Harry Jm Groen, Egbert F Smit, Henk C Hoogsteden, Rudi W Hendriks, Joachim Gjv Aerts, Joost Pjj Hegmans, Immunoglobulin-like transcript 3 is expressed by myeloid-derived suppressor cells and correlates with survival in patients with non-small cell lung cancer OncoImmunology. ,vol. 4, pp. 1014242- ,(2015) , 10.1080/2162402X.2015.1014242
Tian Tian, Xiaobin Gu, Bo Zhang, Yang Liu, Chao Yuan, Lijuan Shao, Yajun Guo, Kexing Fan, Increased circulating CD14(+)HLA-DR-/low myeloid-derived suppressor cells are associated with poor prognosis in patients with small-cell lung cancer. Criminal Behaviour and Mental Health. ,vol. 15, pp. 425- 432 ,(2015) , 10.3233/CBM-150473
Lauren Averett Byers, Charles M. Rudin, Small cell lung cancer: where do we go from here? Cancer. ,vol. 121, pp. 664- 672 ,(2015) , 10.1002/CNCR.29098
Liran Levy, Inbal Mishalian, Rachel Bayuch, Lida Zolotarov, Janna Michaeli, Zvi G Fridlender, Splenectomy inhibits non-small cell lung cancer growth by modulating anti-tumor adaptive and innate immune response. OncoImmunology. ,vol. 4, ,(2015) , 10.1080/2162402X.2014.998469